BioMarin looks for fast approval of hemophilia A gene therapy; Investigators tout Entasis antibiotic
→ BioMarin $BMRN told analysts during its R&D day that new FDA rules may make it possible to file for an FDA approval on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
